![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Estimating the Economic Value Allocation of the Social Surplus Generated by the Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019
|
|
|
![0626231](../images/062623/062623-12/0626231.gif)
EASL 2023 June 21-23 Vienna
Louis P Garrison1,2, Boshen Jiao2,3, Zizi Elsisi1,2, Alon Yehoshua4, Roy Koruth4, Bruce Kreter4, Jens Grueger1,5
1University of Washington, Seattle, WA, USA; 2VeriTech Corporation, Mercer Island, WA, USA; 3Harvard University, T.H. Chan School of Public Health, Cambridge, MA, USA; 4Gilead Sciences, Inc., Foster City, CA, USA; 5Boston Consulting Group, Zurich, Switzerland
![0626231](../images/062623/062623-12/0626231.gif)
![0626232](../images/062623/062623-12/0626232.gif)
![0626233](../images/062623/062623-12/0626233.gif)
![0626234](../images/062623/062623-12/0626234.gif)
![0626235](../images/062623/062623-12/0626235.gif)
![0626236](../images/062623/062623-12/0626236.gif)
![0626237](../images/062623/062623-12/0626237.gif)
![0626238](../images/062623/062623-12/0626238.gif)
![0626239](../images/062623/062623-12/0626239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|